CLL Case Discussion: First Line Treatment Strategies

XV Eurasian Hematology-Oncology Congress - EHOC 2024

CLL Case Discussion: First Line Treatment Strategies

By XV Eurasian Hematology-Oncology Congress - EHOC 2024 FEATURING Damla Ortaboz

60 views

September 6, 2024

CLL Diagnosis & Initial Patient Condition

00:00

Managing Hypogammaglobulinemia in CLL

02:54

Cytogenetic Study & CLL Monitoring

05:43

Chemoimmunotherapy's Role in CLL

06:20

FCR Protocol Efficacy & Risks in CLL

10:44

NCCN Guidelines & Individualized CLL Therapy

12:51

Elderly CLL Patients: Treatment Choices & Concerns

16:30

European Medicine Agency & FDA on CLL Treatments

21:56

CLL Patient Status Post FCR Treatment

22:43

Comments 0

Leukemia

Pediatric ALL: Etiology, Diagnosis and Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

O. TüFekçI GüRocak

23 views

CML Case Discussion: Elderly Patients not Meeting ELN Milestones

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Isam Sharif

9 views

CLL Case: Acquired Del(17p) at Relapse

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Özer Çerme

8 views

ALL Case: B-ALL Arising During Len Maintenance in Myeloma Patient

XV Eurasian Hematology-Oncology Congress - EHOC 2024

K. Ozsoy

Novel Agents in the Treatment of R/R CLL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

44 views

Venetoclax-Based Regimens in AML: Understanding Resistance and Devel…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Daver

120 views

Targeted Therapies in AML With a Focus on FLT3 Inhibitors

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Daver

38 views

A Clinical Case of Extranodal MZL of the Palatum Durum After CLL/SLL…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Ridova

9 views

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

165 views

Ph+ ALL Management: Case-Based Discussion

XV Eurasian Hematology-Oncology Congress - EHOC 2024

K. Koruk

20 views

AML Case Discussion: FLT3-ITD+ High-Risk Disease

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Hindilerden

25 views

Immunotherapy and Sequencing CD19-Targeted Therapies in Adults With …

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

42 views

How I Treat R/R CML in 2024: Strategies and Emerging Therapies

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

26 views

TKI Discontinuation in CML: Defining Eligibility Criteria and Predic…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Yassin

29 views

A Case of CMML With Recurrent Skin Involvement

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Arslan Davulcu

13 views

Critical Re-Evaluation of Established Practices in CML Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

173 views

Management of R/R AML: Treatment Options and Case Insights

XV Eurasian Hematology-Oncology Congress - EHOC 2024

V. Bonuomo

42 views

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

727 views

Practical Approach to MRD Monitoring in AML: Assessing Treatment Eff…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

108 views

Debates in Ph+ ALL: Allo-SCT Should Be Used Upfront in Adult Patients

XV Eurasian Hematology-Oncology Congress - EHOC 2024

D. Hoelzer

31 views

Debates in Ph+ ALL: Allo-SCT Is Not Necessary Upfront in Adult Patie…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

43 views